gene

RNA

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about RNA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

5215Connections

30Hypotheses

16Analyses

50Outgoing

50Incoming

1Experiments

20Debates

Summary

Page for RNA Binding Fox-1 Homolog 2 (RBFOX2)

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	RNA
Aliases	RBFOX2, RBFOX3, RBFOX1
Chromosome	22q12.3
Primary Expression	hippocampus, spinal cord, cortex, cerebellum, prefrontal cortex
Pathways	unfolded protein response, ferroptosis, PI3K-AKT-mTOR signaling, ubiquitin-proteasome, apoptosis pathway
GeneCards	RNA
Human Protein Atlas	RNA
Associated Diseases	aging, Als, Alzheimer, Alzheimer's disease
Known Drugs/Compounds	dimethyl fumarate, ketamine, lecanemab, levodopa, quercetin, rapamycin
Interactions	ABCA7, ABCB1, ACLY, ACTB, Actin, ACVR2A
SciDEX Hypotheses	Cell-state stratification is required to resolve m Perturbation-first validation should precede thera Advancing Beyond Traditional Druggability Through (+1 more)
KG Connections	5213 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

RNA Therapeutics for Neurodegeneration Investment Landscape

investment · 3955 words

→

RNA Metabolism Dysregulation in Alzheimer's Disease

mechanism · 4024 words

→

Validated Hypothesis: Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated Autophagy Through PV Interneuron-Specific ceRNA Networks

hypothesis · 3897 words

→

Pathway Diagram

graph TD
    subgraph Pathology["Pathology"]
        RNA["RNA"] -->|"associated with"| astrocytes["astrocytes"]
    end
    subgraph Signaling["Signaling"]
        RNA["RNA"] -->|"activates"| microglia["microglia"]
        RNA["RNA"] -->|"activates"| SQSTM1["SQSTM1"]
        RNA["RNA"] -->|"activates"| neurodegeneration["neurodegeneration"]
        RNA["RNA"] -->|"regulates"| neurodegeneration_1["neurodegeneration"]
        m6A_Modification["m6A Modification"] -->|"modulates"| RNA["RNA"]
        BECN1["BECN1"] -->|"activates"| RNA["RNA"]
        rapamycin["rapamycin"] -->|"activates"| RNA["RNA"]
        rapamycin_3["rapamycin"] -->|"regulates"| RNA["RNA"]
        Stress_Granules["Stress Granules"] -->|"regulates"| RNA["RNA"]
    end
    subgraph Therapeutic["Therapeutic"]
        RNA["RNA"] -->|"expressed in"| hippocampus["hippocampus"]
        RNA["RNA"] -->|"expressed in"| spinal_cord["spinal cord"]
        rapamycin_4["rapamycin"] -->|"targets"| RNA["RNA"]
    end
    subgraph Interactions["Interactions"]
        RNA["RNA"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
        RNA["RNA"] -->|"interacts with"| neurodegeneration_2["neurodegeneration"]
    end
    style RNA fill:#4a1a6b,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
    style astrocytes fill:#006494,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style microglia fill:#006494,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style hippocampus fill:#90a4ae,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style unfolded_protein_response fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style SQSTM1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style neurodegeneration fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style neurodegeneration_1 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style spinal_cord fill:#90a4ae,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style neurodegeneration_2 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style m6A_Modification fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style BECN1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style rapamycin fill:#90a4ae,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style rapamycin_3 fill:#90a4ae,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style rapamycin_4 fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Stress_Granules fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0

Outgoing (2988)

Target	Relation	Type	Str
neurons	regulates	cell_type	0.90
frontotemporal dementia	interacts_with	disease	0.90
PI3K-AKT-mTOR signaling	participates_in	pathway	0.90
T cells	expressed_in	cell_type	0.90
Alzheimer's disease	regulates	disease	0.90
neurons	expressed_in	cell_type	0.90
ferroptosis	participates_in	pathway	0.90
microglia	associated_with	cell_type	0.90
neurodegeneration	interacts_with	disease	0.90
spinal cord	expressed_in	brain_region	0.90
cortex	expressed_in	brain_region	0.90
stem cells	expressed_in	cell_type	0.90
apoptosis pathway	participates_in	pathway	0.90
neurons	activates	cell_type	0.90
neural stem cells	activates	cell_type	0.90
hippocampus	expressed_in	brain_region	0.90
microglia	activates	cell_type	0.90
astrocytes	associated_with	cell_type	0.90
aging	associated_with	disease	0.90
neurons	associated_with	cell_type	0.90
neural stem cells	treats	cell_type	0.90
neurodegeneration	regulates	disease	0.90
neurodegeneration	activates	disease	0.90
unfolded protein response	participates_in	pathway	0.90
neural stem cells	associated_with	cell_type	0.90
mitochondrial function	participates_in	pathway	0.90
neural stem cells	interacts_with	cell_type	0.90
ubiquitin-proteasome	participates_in	pathway	0.90
astrocytes	activates	cell_type	0.90
neural stem cells	expressed_in	cell_type	0.90
neurons	interacts_with	cell_type	0.90
microglia	expressed_in	cell_type	0.90
neural stem cells	regulates	cell_type	0.90
neural stem cells	inhibits	cell_type	0.90
SQSTM1	activates	gene	0.90
Frailty	biomarker_for	phenotype	0.85
TDP-43	regulates	gene	0.85
TDP-43	activates	gene	0.85
DAM microglia	expressed_in	cell_type	0.85
TDP-43	interacts_with	gene	0.85
Neurodegenerative Diseases	biomarker_for	disease	0.85
autophagy pathway	participates_in	pathway	0.80
YTHDF2	activates	gene	0.80
neurons	protects_against	cell_type	0.80
TFEB	activates	gene	0.80
Parkinson's disease	activates	disease	0.80
prefrontal cortex	expressed_in	brain_region	0.80
CRISPR-Cas	participates_in	pathway	0.80
Alzheimer's disease	activates	disease	0.80
neurons	disrupts	cell_type	0.80

Incoming (2227)

Source	Relation	Type	Str
rapamycin	targets	drug	0.90
DNA	associated_with	gene	0.90
SETX	binds	protein	0.90
BECN1	activates	gene	0.90
Stress Granules	regulates	process	0.90
GABA	activates	gene	0.80
ATG	regulates	gene	0.80
ACTB	activates	gene	0.80
LC3	regulates	gene	0.80
TDP43	binds	protein	0.80
BECN1	regulates	gene	0.80
GABARAP	regulates	gene	0.80
GABA	regulates	gene	0.80
MAP1LC3	activates	gene	0.80
MAP1LC3	regulates	gene	0.80
LAMP1	activates	gene	0.80
ALS	accumulates_in	gene	0.80
ATG	activates	gene	0.80
FUS	causes	gene	0.80
GAPDH	activates	gene	0.80
MAP1LC3B	activates	gene	0.80
DNA	treats	gene	0.80
RBFOX3	activates	gene	0.80
ADAR1	activates	gene	0.80
GABARAP	activates	gene	0.80
LncRNA	interacts_with	biomarker	0.80
G3BP1	interacts_with	gene	0.75
FTLD	regulates	gene	0.70
APOE	interacts_with	gene	0.70
GRN	associated_with	gene	0.70
GLA	activates	gene	0.70
tau protein	interacts_with	protein	0.70
AR	activates	gene	0.70
DNA	accumulates_in	gene	0.70
PI3K	associated_with	gene	0.70
AKT	associated_with	gene	0.70
FUS	treats	gene	0.70
MCOLN1	activates	gene	0.70
ATG	interacts_with	gene	0.70
HCN1	expressed_in	gene	0.70
GBM	treats	gene	0.70
FUS	accumulates_in	gene	0.70
MTORC1	regulates	gene	0.70
GFP	regulates	gene	0.70
BCL2	regulates	gene	0.70
JNK	activates	gene	0.70
LAMP1	regulates	gene	0.70
ATG7	activates	gene	0.70
RAN	regulates	gene	0.70
AMPK	regulates	gene	0.70

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P	0.868	als	-
Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated	0.865	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
SFPQ Paralog Displacement Triggers Cryptic Polyadenylation a	0.864	als	-
hnRNP A2/B1 Staufen2-Mediated Axonal RNA Granule Transport F	0.851	als	-
TDP-43 RNA-proteostasis failure across ALS, FTD, and AD/LATE	0.828	multi	Cross-disease neurodegeneration mechanis

GLE1-Mediated mRNA Export Defect Creates Translation-Compete	0.823	als	-
Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Re	0.804	neurodegeneration	What are the mechanisms by which gut mic
MATR3 Nuclear Body Disruption Impairs RNA Processing Hubs an	0.801	als	-
Stress-granule RNA-binding protein phase transition across A	0.780	multi	Cross-disease neurodegeneration mechanis
METTL3-Mediated m6A Modification of lncRNA-0021 Regulates mi	0.769	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
Seed-Proximal Asymmetric Duplex Stability Confers lncRNA-002	0.733	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
m6A RNA Modification as Address Code for Granule Targeting	0.700	neurodegeneration	What determines the specificity of RNA-p
C9orf72 repeat RNA and dipeptide-repeat toxicity in ALS/FTD	0.700	neurodegeneration	Test
Axonal RNA Transport Reconstitution	0.695	neurodegeneration	RNA binding protein dysregulation across
hnRNPA2B1-Mediated Structural Remodeling Controls lncRNA-002	0.684	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
FUS Phase Separation Dominance in FTD-TDP: Aberrant Condensa	0.683	frontotemporal-dementia	-
Seed match plus local RNA structure jointly determine lncRNA	0.670	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein	0.662	parkinson	m6A RNA Modification and Alpha-Synuclein
RNA Granule Nucleation Site Modulation	0.662	neurodegeneration	TDP-43 phase separation therapeutics for
Mitochondrial RNA Granule Rescue Pathway	0.656	neurodegeneration	RNA binding protein dysregulation across
RNA-binding protein condensate maturation from reversible ph	0.626	neurodegeneration	Causal Sequence of TDP-43 Nuclear Cleara
RNA-binding protein condensate maturation from reversible ph	0.626	neurodegeneration	Biophysical Determinants Shifting FUS/TD
m6A-dependent control of alpha-synuclein transcript fate and	0.626	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
H7: Aberrant RNA Template Switching Converts Granules to Agg	0.625	neurodegeneration	How do pathological stress granules tran
Integrated Blood Panel of sPDGFRβ, sTM, and Circulating micr	0.625	-	What blood-brain barrier permeability ch
RNA-Binding Protein Sequestration and 3′UTR Dysregulation	0.625	-	How does the intron-retained RNA isoform
Synaptic RNA Metabolism Dysregulation	0.620	neurodegeneration	What mechanisms underlie TDP-43's contri
Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Tar	0.613	neurodegeneration	CRISPR-based therapeutic approaches for
Cell-state stratification is required to resolve m6A RNA Mod	0.612	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	m6A RNA Modification and Alpha-Synuclein

Mentioning Analyses (16)

Scientific analyses that reference this entity

Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Ag

neurodegeneration | 2026-04-27 | 4 hypotheses Top: 0.680

m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra

neurodegeneration | 2026-04-27 | 4 hypotheses Top: 0.662

Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Bioma

neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.626

Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Cau

neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.604

How does the intron-retained RNA isoform mechanistically reduce glucocerebrosida

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.645

Experiments (1)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Autophagy receptor identification for stress granule elimination	exploratory	neurodegenerative diseases	0.900	0.00	cultured cells under arsenite	proposed	N/A

Related Papers (15)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiqui [PMID:30966861]	["Han X", "Sun S", "Sun Y", "Song Q", "Z	Autophagy	2020	1
Roles of NAD+ in Health and Aging. [PMID:37848251]	Lautrup S, Hou Y, Fang EF, Bohr VA	Cold Spring Harbor perspective	2024	0
Inhibition of autophagy in microglia and macrophages exacerbates innate immune r [PMID:36652438]	Hegdekar N, Sarkar C, Bustos S, Ritzel R	Autophagy	2023	0
Inflammasome assembly in neurodegenerative diseases. [PMID:37633753]	Singh J, Habean ML, Panicker N	Trends in neurosciences	2023	0
The different autophagy degradation pathways and neurodegeneration. [PMID:35134347]	Fleming A, Bourdenx M, Fujimaki M, Karab	Neuron	2022	0
NLRP3/caspase-1/GSDMD-mediated pyroptosis exerts a crucial role in astrocyte pat [PMID:34877938]	Li S, Sun Y, Song M, Song Y, Fang Y, Zha	JCI insight	2021	0
WDR45 contributes to neurodegeneration through regulation of ER homeostasis and [PMID:31204559]	["Wan Huida", "Wang Qi", "Chen Xiuting",	Autophagy	2020	0
WDR45 contributes to neurodegeneration through regulation of ER homeostasis and [PMID:31204559]	["Wan Huida", "Wang Qi", "Chen Xiuting",	Autophagy	2020	0
Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive defi [PMID:30742114]	Unknown	Nature neuroscience	2019	0
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodeg [PMID:30381407]	Gordon R, Albornoz EA, Christie DC, Lang	Science translational medicine	2018	0
TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Prom [PMID:28817800]	["Mackenzie Ian R", "Nicholson Alexandra	Neuron	2017	0
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem prote [PMID:23455423]	Unknown	Nature	2013	0
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-lin [PMID:21944779]	Unknown	Neuron	2011	0
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. [PMID:17469117]	Unknown	Annals of neurology	2007	0
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic latera [PMID:17023659]	Unknown	Science (New York, N.Y.)	2006	0

Debates (20)

Multi-agent debates referencing this entity

Structured research brief: Stathmin-2 Splice Switching to Prevent Axonal Degener

archived · Rounds: 2 · Score: 0.73 · 2026-04-28

Is microglial priming (TREM2/CX3CR1/complement-C1q) genuinely causally upstream

closed · Rounds: 4 · Score: 0.64 · 2026-04-28

What are the biophysical determinants — RNA binding stoichiometry, post-translat

closed · Rounds: 4 · Score: 0.67 · 2026-04-28

Which non-neuronal cell types (astrocytes, oligodendrocytes, pericytes) exhibit

closed · Rounds: 4 · Score: 0.67 · 2026-04-28

How does N6-methyladenosine (m6A) RNA modification alter alpha-synuclein mRNA st

closed · Rounds: 4 · Score: 0.67 · 2026-04-28

Hypothesis debate: Stathmin-2 Splice Switching to Prevent Axonal Degeneration Ac

closed · Rounds: 4 · Score: 0.49 · 2026-04-27

How does the intron-retained RNA isoform mechanistically reduce glucocerebrosida

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Which specific factors in conditioned medium from healthy astrocytes rescue moto

closed · Rounds: 4 · Score: 0.65 · 2026-04-25

How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what

closed · Rounds: 4 · Score: 0.66 · 2026-04-25

The ASO therapeutic hypothesis assumes dilncRNAs have targetable conserved struc

closed · Rounds: 4 · Score: 0.69 · 2026-04-21

Related Research

Hypotheses and analyses mentioning RNA in their description or question text

Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Release Mechanism for

Score: 0.804 · neurodegeneration · 2026-04-05

## Mechanistic Overview Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Release Mechanism for AIM2 Inflammasom

Stress-granule RNA-binding protein phase transition across ALS and FTD

Score: 0.780 · multi · 2026-04-28

Shared mechanism across ALS, FTD: Low-complexity RNA-binding proteins normally form reversible stress granules, but ALS/

METTL3-Mediated m6A Modification of lncRNA-0021 Regulates miR-6361 Sequestration

Score: 0.769 · molecular-neurobiology · 2026-04-17

## **Molecular Mechanism and Rationale** The methyltransferase-like 3 (METTL3) enzyme functions as the catalytic subuni

Seed-Proximal Asymmetric Duplex Stability Confers lncRNA-0021/miR-6361 Binding S

Score: 0.733 · molecular-neurobiology · 2026-04-17

**Molecular Mechanism and Rationale** The lncRNA-0021/miR-6361 interaction represents a sophisticated regulatory mechan

m6A RNA Modification as Address Code for Granule Targeting

Score: 0.700 · neurodegeneration · 2026-04-21

**Molecular Mechanism and Rationale** The N6-methyladenosine (m6A) RNA modification system represents a sophisticated c

C9orf72 repeat RNA and dipeptide-repeat toxicity in ALS/FTD

Score: 0.700 · neurodegeneration · 2026-04-29

C9orf72 hexanucleotide repeat expansion produces repeat RNA foci and RAN-translated dipeptide-repeat proteins that disru

Axonal RNA Transport Reconstitution

Score: 0.695 · neurodegeneration · 2026-04-02

## Mechanistic Overview Axonal RNA Transport Reconstitution starts from the claim that modulating HNRNPA2B1 within the d

hnRNPA2B1-Mediated Structural Remodeling Controls lncRNA-0021 Accessibility for

Score: 0.684 · molecular-neurobiology · 2026-04-17

## **Molecular Mechanism and Rationale** The proposed therapeutic mechanism centers on the regulatory interplay between

Seed match plus local RNA structure jointly determine lncRNA-0021 binding to mmu

Score: 0.670 · molecular-neurobiology · 2026-04-25

The most likely explanation is a two-factor recognition mechanism: a canonical miRNA seed-complementary site in lncRNA-0

m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein Transcript and Prom

Score: 0.662 · parkinson · 2026-04-27

N6-methyladenosine (m6A) hypermethylation of SNCA mRNA in substantia nigra dopaminergic neurons stabilises the transcrip

RNA Granule Nucleation Site Modulation

Score: 0.662 · neurodegeneration · 2026-04-02

## Mechanistic Overview RNA Granule Nucleation Site Modulation starts from the claim that modulating G3BP1 within the di

Mitochondrial RNA Granule Rescue Pathway

Score: 0.656 · neurodegeneration · 2026-04-02

## Mechanistic Overview Mitochondrial RNA Granule Rescue Pathway starts from the claim that modulating SYNCRIP within th

RNA

Understanding Entity Pages

Summary

Wiki Pages (21)

RNA Therapeutics for Neurodegeneration Investment Landscape

RNA Metabolism Dysregulation in Alzheimer's Disease

Validated Hypothesis: Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated Autophagy Through PV Interneuron-Specific ceRNA Networks

RNA-Targeted Therapies in Neurodegeneration

ALS RNA Metabolism and Proteostasis Failure

RNASEK — Ribonuclease Kappa

C9orf72→RNA/Dipeptide Repeat Pathology→ALS/FTD — Causal Chain

Non-coding RNAs in Neurodegeneration

RNA Toxicity Pathway

TIAL1 — TIA1 Cytotoxic Granule Associated RNA Binding Protein Like 1

RNA Splicing Defects in Neurodegeneration

RNA Stability and Decay

LARS2 — Leucyl-tRNA Synthetase 2, Mitochondrial

IGF2BP3 — Insulin-Like Growth Factor 2 mRNA-Binding Protein 3

PRPF3 — Pre-mRNA Processing Factor 3

TIA1L (TIA1 Cytotoxic Granule-Associated RNA Binding Protein-Like)

RNA Targeting Therapy for Neurodegeneration

RNA Processing in Neurodegeneration

mRNA-Encoded Intrabody for Alpha-Synuclein Clearance

C9orf72 RNA-Targeting Dipeptide Repeat Reduction

RNA Metabolism in Neurodegeneration

Pathway Diagram

Outgoing (2988)

Incoming (2227)

Targeting Hypotheses (30)

Mentioning Analyses (16)

Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Ag

m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra

Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Bioma

Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Cau

How does the intron-retained RNA isoform mechanistically reduce glucocerebrosida

Which specific factors in conditioned medium from healthy astrocytes rescue moto

How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what

scRNA-seq Processing and Cell Type Annotation of AD Brain

Cas13 gRNA Design for Silencing MAPT (Tau) Transcripts in Alzheimer's Disease

RNA binding protein dysregulation across ALS FTD AD

Do chronic stress granule inhibition strategies impair normal cellular stress re

What are the conserved secondary structures in dilncRNAs that enable selective t

What determines the specificity of DDR protein recruitment to dilncRNA-induced c

How do dilncRNAs specifically drive molecular crowding and phase separation of D

Extracellular vesicle biomarkers for early AD detection

RNA binding protein dysregulation across ALS FTD and AD

Experiments (1)

Related Papers (15)

Debates (20)

Structured research brief: Stathmin-2 Splice Switching to Prevent Axonal Degener

Is microglial priming (TREM2/CX3CR1/complement-C1q) genuinely causally upstream

What are the biophysical determinants — RNA binding stoichiometry, post-translat

Which non-neuronal cell types (astrocytes, oligodendrocytes, pericytes) exhibit

How does N6-methyladenosine (m6A) RNA modification alter alpha-synuclein mRNA st

Hypothesis debate: Stathmin-2 Splice Switching to Prevent Axonal Degeneration Ac

How does the intron-retained RNA isoform mechanistically reduce glucocerebrosida

Which specific factors in conditioned medium from healthy astrocytes rescue moto

How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what

The ASO therapeutic hypothesis assumes dilncRNAs have targetable conserved struc

Related Research

Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Release Mechanism for

Stress-granule RNA-binding protein phase transition across ALS and FTD

METTL3-Mediated m6A Modification of lncRNA-0021 Regulates miR-6361 Sequestration

Seed-Proximal Asymmetric Duplex Stability Confers lncRNA-0021/miR-6361 Binding S

m6A RNA Modification as Address Code for Granule Targeting

C9orf72 repeat RNA and dipeptide-repeat toxicity in ALS/FTD

Axonal RNA Transport Reconstitution

hnRNPA2B1-Mediated Structural Remodeling Controls lncRNA-0021 Accessibility for

Seed match plus local RNA structure jointly determine lncRNA-0021 binding to mmu

m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein Transcript and Prom

RNA Granule Nucleation Site Modulation

Mitochondrial RNA Granule Rescue Pathway